Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Trading Down 7.2 %

Shares of NASDAQ EVGN opened at $1.67 on Tuesday. Evogene has a 12-month low of $1.20 and a 12-month high of $10.40. The company has a market cap of $8.97 million, a PE ratio of -0.37 and a beta of 1.30. The stock has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $2.83.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.